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The central role of thrombin in the initiation and propagation of intravascular thrombus
provides a strong rationale for direct thrombin inhibitors in acute coronary syndromes (ACS).
Direct thrombin inhibitors are theoretically likely to be more effective than indirect thrombin
inhibitors, such as unfractionated heparin or low-molecular-weight heparin, because the
heparins block only circulating thrombin, whereas direct thrombin inhibitors block both
circulating and clot-bound thrombin. Several initial phase 3 trials did not demonstrate a
convincing benefit of direct thrombin inhibitors over unfractionated heparin. However, the
Direct Thrombin Inhibitor Trialists’ Collaboration meta-analysis confirms the superiority of
direct thrombin inhibitors, particularly hirudin and bivalirudin, over unfractionated heparin
for the prevention of death or myocardial infarction (MI) during treatment in patients with
ACS, primarily due to a reduction in MI (odds ratio, 0.80; 95% confidence interval, 0.70 to
0.91) with little impact on death. The absolute risk reduction in the composite of death or MI
at the end of treatment (0.8%) was similar at 30 days (0.7%), indicating no loss of benefit after
cessation of therapy. Supportive evidence for the superiority of direct thrombin inhibitors over
heparin derives from the recently reported Hirulog and Early Reperfusion or Occlusion
(HERO)-2 randomized trial with ST-segment elevation ACS, which demonstrated a similar
benefit of bivalirudin over heparin for the prevention of death or MI at 30 days (absolute risk
reduction 1.0%), again primarily due to a reduction in MI during treatment (odds ratio, 0.70;
95% confidence interval, 0.56 to 0.87), with little impact on death. Further evaluation of
hirudin and bivalirudin in the antithrombotic management of patients with ACS is
warranted. (J Am Coll Cardiol 2003;41:70S–78S) © 2003 by the American College of
Cardiology Foundation
The most common underlying pathophysiologic process in
patients with non–ST-segment elevation acute coronary
syndromes (ACS) involves the formation of nonocclusive
thrombus at the site of vessel wall injury (1,2). Spontaneous
or mechanical disruption of atherosclerotic plaque exposes
thrombogenic material within the plaque to the blood,
which leads to platelet adhesion and aggregation, coagula-
tion activation, and thrombin generation (3). Thrombin
plays a central role in the process of thrombus formation,
converting fibrinogen to fibrin, activating platelets, and
recruiting additional platelets into the platelet-rich throm-
bus. The resulting intracoronary thrombus reduces myocar-
dial perfusion and leads to unstable angina or acute myo-
cardial infarction (MI).
Recognition of the pivotal role of thrombin in the
initiation and propagation of intracoronary thrombus for-
mation has led to intensive efforts to develop new therapies
that block thrombin generation or activity (4). Unfraction-
ated heparin (UFH) and low-molecular-weight heparin
(LMWH) indirectly inhibit thrombin through an
antithrombin-dependent mechanism and are widely used in
the management of arterial and venous thrombosis. In
aspirin-treated patients with non–ST-segment elevation
ACS, the addition of heparin is associated with a 30%
reduction in the risk of recurrent MI or death during the
first week (5). An important limitation of heparin, however,
is its inability to inhibit clot-bound thrombin (Fig. 1).
When thrombin is bound to fibrin, to soluble fibrin degra-
dation products, or to exposed subendothelial matrix pro-
teins, it is protected from inactivation by heparin but
remains enzymatically active. In such a scenario, thrombin is
able to amplify its own generation through a positive
feedback loop via coagulation factors V and VIII, thereby
continuing to promote thrombus formation (6,7).
Direct thrombin inhibitors have important biologic and
pharmacokinetic advantages over heparins (Table 1) (8).
Direct thrombin inhibitors are able to specifically block both
fluid-phase and tissue-bound thrombin and, therefore, re-
duce thrombin activity more effectively than UFH and
LMWH (Fig. 1). Because they do not bind to plasma proteins
and are not inactivated by heparinases, direct thrombin inhib-
itors also produce a more predictable anticoagulant response
than UFH. Experimental results have shown that direct
thrombin inhibitors are highly effective in the prevention of
thrombus formation in models of arterial thrombosis (9,10).
The accumulating evidence has led to a large number of clinical
trials of direct thrombin inhibitors in patients with ACS (11).
Please refer to the Trial Appendix at the back of this supplement for the complete list
of Clinical Trials.
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The objectives of this paper are twofold: 1) to review the
results of randomized clinical trials of direct thrombin
inhibitors compared with UFH in patients with ACS
overall, and subdivided, according to the absence or pres-
ence of persistent ST-segment elevation on the presentation
electrocardiogram; and 2) to discuss the current role of
direct thrombin inhibitors for the management of patients
with ACS in the context of emerging anticoagulant and
antiplatelet therapies, particularly glycoprotein (GP) IIb/
IIIa inhibitors.
DIRECT THROMBIN INHIBITORS
The prototype direct thrombin inhibitor is hirudin, a
naturally occurring 65-amino acid polypeptide first isolated
from the salivary gland of medicinal leeches and now
available through recombinant DNA technology (12).
Many other direct thrombin inhibitor preparations have
been developed, but only those that have been evaluated in
patients with ACS are listed in Table 2.
Hirudin is a potent and almost irreversible inhibitor of
thrombin, blocking the active catalytic site as well as the
substrate recognition exosite (13). It has a half-life of
approximately 60 min after intravenous administration and
is primarily excreted through the kidneys, which may lead to
its accumulation in patients with renal impairment. A
polyethylene glycol-complexed preparation, PEG-hirudin,
with an extended half-life, has also been developed.
Bivalirudin is a 20-amino acid polypeptide that was
synthesized by linking an active site-directed, short-peptide
chain to an analogue of the carboxy-terminal of hirudin
(14). Consequently, bivalirudin, like hirudin, is able to form
a bivalent complex with thrombin, blocking both the active
site and the substrate recognition exosite. However, it has a
substantially shorter plasma half-life of 20 to 25 min
because of cleavage by thrombin of the active site-binding
peptide. This may provide two important advantages to
bivalirudin. First, it may grant a safety advantage for
bivalirudin over hirudin by allowing earlier re-exposure of
the active site of thrombin, permitting hemostasis to occur.
Second, it may confer an efficacy advantage by allowing
thrombin activation of the natural anticoagulant, protein C
(15). Bivalirudin is excreted primarily via nonrenal mecha-
nisms.
Several synthetic univalent direct thrombin inhibitors
have been evaluated in phase 1 and 2 ACS trials, including
the noncovalent inhibitors argatroban and inogatran and the
reversible covalent inhibitor efegatran (16 –18). These
agents target only the active site of thrombin, have a short
half-life, and appear to be more potent inhibitors of fibrin-
bound thrombin than the bivalent inhibitors hirudin and
bivalirudin (6,19).
RANDOMIZED DIRECT
THROMBIN INHIBITOR TRIALS IN ACS
Major phase 3 randomized trials that have been performed
in patients with ACS are summarized in Tables 3 and 4.
Hirudin. Initial studies demonstrating the feasibility of
hirudin as an anticoagulant in patients with stable or
unstable coronary disease (20–23) were followed by phase 2
heparin-controlled trials in patients with ACS based on
angiographic or clinical outcomes (24–29). Several angio-
graphic studies demonstrated improvements in coronary
artery patency with hirudin compared with heparin (24–
26), while the initial clinical trials revealed promising
reductions in important clinical outcomes during treatment
(27–29). These results prompted several study groups to
initiate a series of major phase 3, randomized, heparin-
controlled, direct thrombin inhibitor trials in ACS, includ-
ing the Global Utilization of Streptokinase and Tissue
plasminogen activator for Occluded coronary arteries
(GUSTO), Hirudin for Improvement of Thrombolysis
(HIT), Thrombolysis In Myocardial Infarction (TIMI),
Organization to Assess Strategies for Ischemic Syndromes
Figure 1. Schematic demonstrating the antithrombin activity of heparin
compared with direct thrombin inhibitors. Both heparin and direct
thrombin inhibitors block circulating thrombin, but only direct thrombin
inhibitors block tissue-bound thrombin. Tissue-bound thrombin remains
enzymatically active, promoting further platelet and coagulation activation
and thrombin generation.
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
aPPT  activated partial thromboplastin time
GP  glycoprotein
LMWH  low-molecular-weight heparin
MI  myocardial infarction
PEG  polyethylene glycol
RR  relative risk
UFH  unfractionated heparin
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(OASIS), and, most recently, Hirulog and Early Reperfu-
sion or Occlusion (HERO).
Three trials (GUSTO-2A, TIMI-9A, and HIT-3) were
stopped due to excessive bleeding. In GUSTO-2A (30),
investigators randomized ACS patients to a 72- to 120-h
infusion of either hirudin (0.6 mg/kg bolus, 0.2 mg/kg/h
infusion) or UFH, with a target activated partial thrombo-
plastin time (aPPT) of 60 to 90 s for UFH and no dose
adjustment for hirudin. Excessive intracranial bleeding oc-
curred primarily in patients receiving thrombolytic therapy
(incidence 1.8%) with only 0.3% occurring in the non–ST-
segment elevation ACS group.
The TIMI-9A trial (31) randomly assigned patients with
ST-segment elevation ACS receiving thrombolytic therapy
to 96 h of treatment with hirudin (0.6 mg/kg bolus, 0.2
mg/kg/h infusion) or UFH. The Data and Safety Monitor-
ing Board terminated the trial prematurely because of a high
rate of hemorrhagic complications in both treatment
groups, particularly in the hirudin group.
In the HIT-3 study (32), patients were randomized to 48
to 72 h of either hirudin (0.4 mg/kg bolus, 0.15 mg/kg/h
infusion) or heparin as an adjunct to tissue plasminogen
activator. The dose of both hirudin and UFH was adjusted
during infusion to a target aPTT ratio of 2.0 to 3.5. The
trial was terminated early because of an excess of intracranial
bleeds in patients receiving hirudin (3.4% vs. 0%, p  NS).
The GUSTO-2B (33) and TIMI-9B (34) trials were
subsequently recommenced with lower doses of both hiru-
din (0.1 mg/kg bolus, 0.1 mg/kg/h infusion) and UFH, with
a target aPTT of 60 to 85 s and 55 to 85 s, respectively. The
projected recruitment was successfully achieved in both
studies. In the GUSTO-2B trial at 30 days there was a
borderline significant reduction in the primary composite
outcome of death or MI with hirudin compared with UFH
(odds ratio [OR], 0.89; 95% confidence interval [CI], 0.79
to 1.00), with consistent results when compared as an
adjunct to thrombolysis or in non–ST-segment elevation
ACS. In the TIMI-9B trial there was no benefit of hirudin
over UFH at 30 days, either on the primary composite
outcome of death, MI, cardiac failure, or cardiogenic shock
or the composite of death or MI. However, there was a
trend to reduction in nonfatal MI both during hospitaliza-
tion and at 30 days. Neither GUSTO-2B nor TIMI-9B
demonstrated an excess of major or intracranial bleeding
with hirudin compared with heparin.
The OASIS-2 trial (35) randomized 10,141 patients with
non–ST-segment elevation ACS to a 72-h infusion of
hirudin (0.4 mg/kg bolus, 0.15 mg/kg/h infusion) or UFH,
with a target aPTT of 60 to 100 s. This study demonstrated
a nonsignificant difference between hirudin and heparin in
the primary outcome of cardiovascular death or MI at seven
days (3.6% vs. 4.2%). However, at the completion of study
drug infusion, there was a significant reduction in cardio-
vascular death or MI with hirudin relative to heparin (2.0%
vs. 2.6%). Compared with UFH, hirudin was associated
with a significantly increased risk of major bleeding (1.2%
vs. 0.7%), but not life-threatening bleeding (0.4% vs. 0.4%).
There were no cases of intracranial bleeding during study
drug infusion with hirudin and one case with UFH.
A pooled analysis of the OASIS, GUSTO-2B, and
TIMI-9B trials confirms the superiority of hirudin com-
pared with heparin for the prevention of death or MI at the
completion of treatment (relative risk [RR], 0.78; p 
0.0004), 7 days (RR, 0.84; p  0.002), and 30 to 35 days
(RR, 0.90; p  0.016) (35).
Table 2. Direct Thrombin Inhibitors Evaluated in Randomized
Trials of Patients With ACS
Trial Phase
Acute Coronary Syndromes
Non–ST-Segment
Elevation
ST-Segment
Elevation
Phase 1 or 2 Argatroban Argatroban
Bivalirudin Bivalirudin
Efegatran Efegatran
Hirudin (PEG-hirudin*) Hirudin
Inogatran
Phase 3 Bivalirudin† Bivalirudin
Hirudin Hirudin
*Pilot studies also have been performed with a PEG-complexed form of hirudin;
†Study abandoned by sponsoring company before completion.
ACS  acute coronary syndromes; PEG  polyethylene glycol.
Table 1. Advantages of Direct Thrombin Inhibitors Over Heparins
Unfractionated
Heparin
Low-Molecular-
Weight Heparin
Direct
Thrombin
Inhibitor
Pharmacokinetic
Plasma protein/endothelial binding Yes Partial No
Inactivated by heparinases Yes Partial No
Biologic effects
Anticoagulant effects Xa  IIa Xa  IIa IIa
Antithrombin-dependent Yes Yes No
Inactivates clot-bound thrombin No No Yes
Inhibits platelet function Yes (paradoxical
activation?)
Limited Yes, thrombin-
induced only
Vascular permeability Increased Not increased Not increased
Thrombocytopenia Yes Rare No
Liver toxicity (enzyme rise) Common Uncommon No
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Bivalirudin. After uncontrolled studies that demonstrated
the feasibility of bivalirudin (36,37), several highly promis-
ing heparin-controlled pilot studies were performed with
bivalirudin in patients with ACS (38–40). A meta-analysis
of these trials (41) that included data from patients under-
going percutaneous coronary intervention (42,43) confirmed
the superiority of bivalirudin over heparin for the prevention
of death or MI at 30 to 50 days (OR, 0.73; 95% CI, 0.57 to
0.95) with a reduction in risk of major bleeding (OR, 0.41;
95% CI, 0.32 to 0.52). This meta-analysis also included data
from the prematurely terminated (for “business” reasons by
the sponsors) phase 3 TIMI-8 trial that compared a 72-h
infusion of bivalirudin with heparin in patients with non–
ST-segment elevation ACS (target enrolment 5,320). Al-
though only 133 patients were randomized before study
termination, there was already a highly promising reduction
in the risk of death or MI with bivalirudin compared with
UFH at 14 days (2.9% vs. 9.2%) (44).
Further evidence of the superiority of bivalirudin over
heparin in ACS derives from the recently completed
HERO-2 study (45). This trial randomized 17,073 patients
with acute MI receiving thrombolytic therapy to a 48-h
infusion of bivalirudin or heparin. In order to test the
hypothesis that exposure of tissue-bound thrombin by
thrombolytic therapy is an important trigger for recurrent
ischemic events, bivalirudin and heparin were administered
before thrombolytic therapy. In the absence of major bleed-
ing, dose reduction of bivalirudin was not allowed after 12 h
Table 3. Phase 3 Trials Comparing Direct Thrombin Inhibition With Heparin in ACS
Trials (DTI) Patients (n) Primary End Point
Dose: Bolus (mg/kg); Infusion
(mg/kg/h)/Duration of Infusion
GUSTO-2A* (Hirudin) ACS (2,564) Death or MI at 30 days 0.6; 0.2/72–120 h
GUSTO-2B (Hirudin) ACS (12,142) Death or MI at 30 days 0.1; 0.1/72 h
HERO-2 (Bivalirudin) ST-segment elevation ACS (17,073) Death at 30 days 0.25; 0.5/12 h, followed by
0.25/36 h
HIT-3* (Hirudin) ST-segment elevation ACS (302) Death or MI 0.4; 0.15/48–72 h
TIMI-9A* (Hirudin) ST-segment elevation ACS (757) Death, MI, CHF, cardiogenic shock, or
LVEF  40% at 30 days
0.6; 0.2/96 h
TIMI-9B (Hirudin) ST-segment elevation ACS (3,002) Death, MI, CHF, cardiogenic shock, or
LVEF  40% at 30 days
0.1; 0.1/96 h
OASIS-2 (Hirudin) Non–ST-segment elevation ACS (10,132) Cardiovascular death or MI at 7 days 0.4; 0.15/72 h
TIMI-8† (Bivalirudin) Non–ST-segment elevation ACS (133) Death or MI at 14 days 0.1; 0.25/72 h
*Stopped early by data safety monitoring board due to high rates of bleeding; †Study abandoned by sponsoring company before completion (planned enrolment 5,320).
ACS acute coronary syndromes; CHF congestive heart failure; DTI direct thrombin inhibitor; GUSTOGlobal Utilization of Streptokinase and Tissue plasminogen
activator for Occluded coronary arteries; HERO  Hirulog and Early Reperfusion or Occlusion; HIT  Hirudin for Improvement of Thrombolysis; LVEF  left ventricular
ejection fraction; MI  myocardial infarction; OASIS  Organization to Assess Strategies for Ischemic Syndromes; TIMI  Thrombolysis In Myocardial Infarction.
Table 4. Results of Completed Phase 3 Trials of Direct Thrombin Inhibitors Compared With
Heparin in ACS
Trials Results Odds Ratio 95% CI
GUSTO-2B With hirudin:
Reduction in death or MI 0.89 0.79–1.00
As adjunct to thrombolysis 0.86 0.70–1.05
Non–ST-segment elevation 0.90 0.78–1.06
HERO-2 With bivalirudin:
No difference in death at 30 days 0.99 0.90–1.09
Reduced death or MI at 30 days 0.92 0.83–1.01
Reduced MI at 96 h 0.70 0.56–0.87
Increased bleeding 1.32 1.00–1.74
Reduced death, MI, nonfatal stroke, 30 days 0.91 0.83–1.00
TIMI-9B No benefit with hirudin
Primary end point 1.09 0.80–1.31
Composite of death or MI 1.02 0.80–1.31
Trend to less nonfatal MI
In hospital 0.65 0.42–1.01
At 30 days 0.81 0.56–1.18
OASIS-2 No difference in primary outcome at 7 days: 0.84 0.69–1.02
With hirudin:
Less cardiovascular death or MI at end of treatment 0.76 0.59–0.99
More major bleeding 1.73 1.13–2.63
No more life-threatening bleeding 0.99 0.54–1.85
ACS  acute coronary syndromes; CI  confidence interval; GUSTO  Global Utilization of Streptokinase and Tissue
plasminogen activator for Occluded coronary arteries; HEROHirulog and Early Reperfusion or Occlusion; MI myocardial
infarction; OASIS  Organization to Assess Strategies for Ischemic Syndromes; TIMI  Thrombolysis In Myocardial
Infarction.
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unless the aPTT was 150 s, or after 24 h unless the aPTT
was 120 s.
The HERO-2 study demonstrated no difference in the
primary outcome of death at 30 days in patients treated with
bivalirudin compared with heparin. There was, however, an
8% reduction in the composite of death or MI at 30 days
and a 30% reduction in the incidence of new MI at 96 h, a
benefit that was maintained to 30 days. Modest excess
bleeding occurred with bivalirudin compared with heparin
(1.4% vs. 1.1%) with a similar trend for severe excess
bleeding (0.7% vs. 0.5%, p  0.07). This was somewhat
unexpected in view of the reduced risk of bleeding seen in
earlier studies performed with this agent, but may be due to
the higher aPTT levels at 12 h (median aPPT, 108 vs. 77 s;
p  0.0001) and 24 h (median aPPT, 80 vs. 57 s; p 
0.0001) in patients receiving bivalirudin compared with
heparin. However, the incidence of moderate (major) and
intracranial hemorrhage in this trial remained low compared
with contemporary thrombolysis trials in patients with
ACS, and the composite net clinical benefit outcome of
death, MI, and nonfatal disabling stroke at 30 days favored
bivalirudin (p  0.049).
Univalent direct thrombin inhibitors. There has been
only limited evaluation of univalent direct thrombin inhib-
itors in ACS, and the results have largely been disappoint-
ing. Although these agents were generally well tolerated
with no excess major bleeding compared with heparin, most
of the phase 2 trials were unable to demonstrate superiority
of argatroban, efegatran, or inogatran compared with hep-
arin, based on surrogate (angiographic, electrocardio-
graphic) or clinical outcomes. In some cases the results
suggested that they may be inferior (46–49).
DIRECT THROMBIN INHIBITOR
TRIALISTS’ COLLABORATION META-ANALYSIS
Despite several large, randomized trials, there has been
uncertainty regarding the clinical benefit of direct thrombin
inhibitors compared with heparin in patients with ACS,
whether early treatment benefits are maintained long-term,
and whether excess bleeding offsets any benefit of these
agents. The reasons for this uncertainty include the possi-
bility that direct thrombin inhibitors are not superior to
UFH. Alternatively, the benefits may be modest, and larger
trials than those conducted may be needed. Further, several
of the trials may have chosen to measure the outcome
several days or weeks after cessation of treatments, so that
any real benefit may have been “diluted” by events occurring
subsequent to treatment cessation.
To address these issues, the Direct Thrombin Inhibitor
Trialists’ Collaboration recently reported the results of a
systematic review of major randomized trials of direct
thrombin inhibitors compared with UFH in patients with
unstable coronary disease (11,50). Trials included in the
meta-analysis had to randomize patients with ACS or
patients undergoing percutaneous coronary intervention,
compare a direct thrombin inhibitor with heparin, and
record data on the key irreversible outcomes of death and
MI. The primary outcome was the composite of death or
MI at the end of treatment when the maximal benefit of
antithrombotic therapy is likely to be evident. Outcomes at
day 7 and day 30 also were examined. Small trials (200
patients or 100 controls) and trials performed with exces-
sive doses of direct thrombin inhibitor or heparin (TIMI-
9A, GUSTO-2A, HIT-3) were not included.
Overall, there was a 15% reduction in death or MI at the
end of treatment with direct thrombin inhibitors compared
with heparin (4.3% vs. 5.1%; OR, 0.85; 95% CI, 0.77 to
0.94; p  0.001), equivalent to preventing eight events for
every 1,000 patients treated (50) (Table 5). This absolute
reduction in death or MI was maintained to 30 days (Table
6). A similar benefit was evident in all categories of trials,
including ACS, and subdivided according to ST-segment
elevation or non–ST-segment elevation (Table 5). The
benefit was seen with hirudin (OR, 0.83; 95% CI, 0.74 to
Table 5. Direct Thrombin Inhibitor Trialists’ Collaboration: Direct Thrombin Inhibitors
Compared With Heparin in Patients With ACS With or Without ST-Segment Elevation at the
End of Treatments
Outcomes
DTI
(n  15,866)
Heparin
(n  14,651) OR (95% CI)
Death or MI
ACS 726/15,866 (4.6%) 786/14,651 (5.4%) 0.85 (0.76–0.94)
ACS with ST-segment elevation 325/5,148 (6.3%) 332/4,799 (6.9%) 0.91 (0.77–1.06)
ACS without ST-segment elevation 401/10,718 (3.7%) 454/9,852 (4.6%) 0.80 (0.70–0.92)
Death
ACS 353/15,866 (2.2%) 343/14,651 (2.3%) 0.95 (0.82–1.10)
ACS with ST-segment elevation 213/5,148 (4.1%) 186/4,799 (3.9%) 1.07 (0.88–1.31)
ACS without ST-segment elevation 140/10,718 (1.3%) 157/9,852 (1.6%) 0.82 (0.65–1.03)
MI
ACS 434/15,866 (2.7%) 499/14,651 (3.4%) 0.80 (0.70–0.91)
ACS with ST-segment elevation 130/5,148 (2.5%) 161/4,799 (3.4%) 0.75 (0.59–0.94)
ACS without ST-segment elevation 304/10,718 (2.8%) 338/9,852 (3.4%) 0.82 (0.70–0.96)
Data adapted from reference 50. Reprinted with permission from Elsevier Science (Lancet 2002;359:294–302).
ACS  acute coronary syndrome; CI  confidence interval; DTI  direct thrombin inhibitor; MI  myocardial infarction;
OR  odds ratio.
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0.92) and bivalirudin (OR, 0.53; 95% CI, 0.24 to 1.17) but
not univalent thrombin inhibitors (OR, 1.35; 95% CI, 0.89
to 2.05). The greatest benefit of direct thrombin inhibitors
compared with heparin appeared to be in patients undergo-
ing percutaneous coronary intervention during study infu-
sion, where there was a 32% reduction in death or MI (4.6%
vs. 6.6%; OR, 0.68; 95% CI, 0.57 to 0.83).
Although direct thrombin inhibitors compared with hep-
arin were not associated with an overall excess of major
bleeding or intracranial bleeding in the ACS trials, pooled
results from all the trials (including percutaneous coronary
intervention trials) demonstrated that hirudin was associ-
ated with an increased risk of major bleeding (1.7% vs. 1.3%;
OR, 1.28; 95% CI, 1.06 to 1.55), while both bivalirudin
(4.2% vs. 9.0%; OR, 0.44; 95% CI, 0.34 to 0.56) and
univalent inhibitors (0.7% vs. 1.3%; OR, 0.55; 95% CI, 0.25
to 1.20) were associated with a reduced risk of major
bleeding. The shorter half-life and a more transient inhibi-
tion of the active site of thrombin may account for the
reduced risk of major bleeding associated with bivalirudin
compared with hirudin (51), although this was not con-
firmed in the HERO-2 trial (45).
CURRENT ROLES AND FUTURE
DIRECTIONS OF DIRECT THROMBIN INHIBITORS IN ACS
The consistent results of the HERO-2 trial (45), hirudin
(35) and bivalirudin (41) meta-analyses, and Direct Throm-
bin Inhibitor Trialists’ Collaboration meta-analysis (50)
provide clear evidence for the superiority of the direct
thrombin inhibitors, particularly hirudin and bivalirudin,
over heparin in ACS, with or without ST-segment eleva-
tion. Although the bulk of the randomized evidence in
non–ST-segment elevation ACS derives from trials com-
paring hirudin with heparin, the consistency of the treat-
ment effects of bivalirudin in patients with ST-segment
elevation and undergoing percutaneous coronary interven-
tion suggests that this agent is likely to be similarly effective
in patients without ST-segment elevation. By contrast,
there are currently no data supporting the use of univalent
direct thrombin inhibitors in patients with ACS.
There are a number of unresolved issues. First, the greater
efficacy of direct thrombin inhibitors in reducing death or
MI in patients with ACS is balanced, in part, by an excess
of major bleeding, particularly with hirudin, which may
limit its use to patients at highest risk of future vascular
events in whom the benefits are more likely to outweigh the
bleeding risks. One such high-risk group may be patients
with ACS undergoing percutaneous coronary intervention
in whom both the relative and absolute benefits of hirudin
in reducing death or MI appear to be greatest (50,52).
Second, available trials comparing hirudin with UFH in
patients with ACS were largely performed before the
widespread use of intravenous GP IIb/IIIa inhibitors. How-
ever, intravenous GP IIb/IIIa inhibitor agents appear to be
beneficial only when administered in combination with
heparin and compared against placebo (53). Furthermore,
indirect comparison of trials comparing the incremental
benefit of direct thrombin inhibitors versus UFH, and GP
IIb/IIIa inhibitors plus UFH, versus UFH alone, indicate a
similar magnitude of benefit on end-of-treatment (RR
reduction of 15% and 16%, respectively) and 30-day (RR
reduction of 8% and 9%, respectively) outcomes of death
and MI (Table 7, Fig. 2). The reason for this may be that
direct thrombin inhibitors have both anticoagulant and
antiplatelet properties (54), while GP IIb/IIIa inhibitors
have only antiplatelet activity and require the addition of an
anticoagulant, such as heparin, to block coagulation. This
suggests a possible role for direct thrombin inhibitors as a
single drug that replaces the combination of GP IIb/IIIa
inhibitors and heparin in patients with ACS, particularly
high-risk patients undergoing percutaneous coronary inter-
vention. At least one study comparing bivalirudin with or
without a GP IIb/IIIa inhibitor versus UFH plus a GP
IIb/IIIa inhibitor (Randomized Evaluation in PCI Linking
Angiomax to Reduced Clinical Events [REPLACE] trial)
is further testing this hypothesis (55).
Table 6. Direct Thrombin Inhibitor Trialists’ Collaboration: DTI Compared With Heparin in
Patients With ACS With or Without ST-Segment Elevation at 30 Days
Outcomes
DTI
(n  15,866)
Heparin
(n  14,651) OR (95% CI)
Death or MI
ACS 1,288 (8.1%) 1,285 (8.8%) 0.92 (0.85–1.00)
ACS with ST-segment elevation 506 (9.8%) 489 (10.2%) 0.96 (0.84–1.10)
ACS without ST-segment elevation 782 (7.3%) 796 (8.1%) 0.90 (0.81–0.99)
Death
ACS 672 (4.2%) 629 (4.3%) 0.99 (0.88–1.10)
ACS with ST-segment elevation 317 (6.2%) 271 (5.6%) 1.10 (0.93–1.30)
ACS without ST-segment elevation 355 (3.3%) 358 (3.6%) 0.91 (0.78–1.05)
MI
ACS 771 (4.9%) 800 (5.5%) 0.88 (0.80–0.98)
ACS with ST-segment elevation 228 (4.4%) 254 (5.3%) 0.83 (0.69–1.00)
ACS without ST-segment elevation 543 (5.1%) 546 (5.5%) 0.91 (0.81–1.03)
Data adapted from reference 50. Reprinted with permission from Elsevier Science (The Lancet, 2002;359:294–302).
ACS  acute coronary syndrome; CI  confidence interval; DTI  direct thrombin inhibitors; MI  myocardial infarction;
OR  odds ratio.
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It is interesting to compare the development of the direct
thrombin inhibitor and that of the intravenous GP IIb/IIIa
inhibitors. The latter agents were initially tested in patients
undergoing percutaneous coronary intervention (Evaluation
of IIb/IIIa Platelet receptor antagonist 7E3 in preventing
Ischemic Complications [EPIC]) (56), a scenario in which
patients were treated before mechanical rupturing of plaques
by balloon angioplasty. In EPIC, outcomes were measured
relatively early (at 30 days), and the benefits of GP IIb/IIIa
inhibitors compared with heparin were relatively large (RR
reduction, 35%). Subsequent trials of GP IIb/IIIa inhibitors
in ACS have shown much more modest benefits, especially
when percutaneous coronary intervention rates were not
high (53). By contrast, although there was an early trial of
direct thrombin inhibitors in percutaneous coronary inter-
vention (Hirudin in a European restenosis prevention triaL
VErsus heparin Treatment In PTCA patients [HEL-
VETICA]) (57), outcomes were measured late (180 days).
However, the 30-day outcomes for the prevention of the
composite outcome of death or MI were similar in HEL-
VETICA and EPIC (RR reduction of 39% and 35%,
respectively). Most subsequent trials of direct thrombin
inhibitors were in broad populations with ACS where the
overall benefits, compared with heparin, are almost identical
to the overall benefits of GP IIb/IIIa inhibitors versus
placebo when added to heparin in patients with ACS (53).
These considerations raise the possibility that direct throm-
bin inhibitors (at least hirudin and bivalirudin) are similar in
efficacy to GP IIb/IIIa inhibitors, and further suggest that
the sequence and types of trials may have affected the
Table 7. Indirect Comparison of the Relative Efficacy and Safety of Direct Thrombin Inhibitors Versus Heparin With GP IIb/IIIa
Inhibitors Versus Heparin in Patients With Acute Coronary Syndrome Trials
Outcomes
Direct Thrombin Inhibitors vs. Heparin GP IIb/IIIa Inhibitors vs. Heparin
DTI
(n  15,866)
Heparin
(n  14,651)
OR
(95% CI) RRR
GP IIb/IIIa
(n  18,297)
Heparin
(n  13,105) OR (95% CI) RRR
End of Rx*
Death/MI 726 (4.6%) 786 (5.4%) 0.85 (0.76–0.94) 15% 1,042 (5.7%) 901 (6.9%) 0.84 (0.77–0.93) 16%
MI† 434 (2.7%) 499 (3.4%) 0.80 (0.70–0.91) 20% 821 (4.5%) 733 (5.6%) 0.83 (0.75–0.92) 17%
Death 353 (2.2%) 343 (2.3%) 0.95 (0.82–1.10) 5% 221 (1.2%) 168 (1.3%) 0.93 (0.76–1.14) 7%
30 days
Death/MI 1,288 (8.1%) 1,285 (8.8%) 0.92 (0.85–1.00) 8% 1,980 (10.8%) 1,550 (11.8%) 0.91 (0.85–0.98) 9%
MI† 771 (4.9%) 800 (5.5%) 0.88 (0.80–0.98) 12% 1,349 (7.4%) 1,065 (8.1%) 0.92 (0.85–1.00) 8%
Death 672 (4.2%) 629 (4.3%) 0.99 (0.88–1.10) 1% 631 (3.4%) 485 (3.7%) 0.91 (0.81–1.03) 9%
Direct thrombin inhibitor and GP IIb/IIIa data adapted with permission from Elsevier Science (Lancet 2002:359:294–302 and Lancet 2002;359:189–98).
*Outcomes from direct thrombin inhibitor trials are at end of protocol-defined treatment  24 h; outcomes from GP IIb/IIIa inhibitor trials are at five days; †direct thrombin
inhibitor data are for fatal plus nonfatal myocardial infarction; GP IIb/IIIa inhibitor data are for nonfatal MI.
DTI  direct thrombin inhibitor; GP IIb/IIIa  glycoprotein IIb/IIIa inhibitor; MI  myocardial infarction; OR  odds ratio; RRR  relative risk reduction; RX 
treatment.
Figure 2. Indirect comparison of the relative efficacy and safety of direct thrombin inhibitors versus heparin with glycoprotein (GP) IIb/IIIa inhibitors versus
heparin in trials of patients with acute coronary syndrome. Direct thrombin inhibitor and GP IIb/IIIa data are adapted from references 50 and 53,
respectively. CI  confidence interval; DTI  direct thrombin inhibitor; MI  myocardial infarction; OR  odds ratio. Reprinted with permission from
Elsevier Science (Lancet 2002:359;294–302 and Lancet 2002:359;189–98).
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perception of their efficacy. The REPLACE trial will be of
great scientific and medical importance as it is likely to
further clarify the relative “merits” of these two classes of
agents.
Finally, randomized trials of direct thrombin inhibitors in
patients with non–ST-segment elevation ACS were per-
formed before the widespread use of clopidogrel (58),
LMWH (5), and third-generation fibrin-specific thrombo-
lytic agents (59). Further data are required to determine the
efficacy and safety of direct thrombin inhibitors in the
context of current antithrombotic strategies before they can
be used in routine clinical practice in patients with ACS.
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